X
API Suppliers
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
EU WC
0
Listed Suppliers
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
AN2025 (buparlisib ) is an oral pan-PI3K inhibitor, It is being evaluated in combination with paclitaxel for the treatment of recurrent or metastatic head and neck squamous cell carcinoma.
Lead Product(s): Buparlisib,Paclitaxel
Therapeutic Area: Oncology Product Name: AN2025
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 17, 2023
Details:
The net proceeds will fund the ongoing registrational trial for AN2025 (buparlisib), an oral pan-PI3K inhibitor that targets all class I PI3K isoforms, the milestone payments in connection with development of AN2025 and the commercial launch, if approved, of AN2025.
Lead Product(s): Buparlisib,Paclitaxel
Therapeutic Area: Oncology Product Name: AN2025
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Cantor Fitzgerald & Co.
Deal Size: $57.5 million Upfront Cash: Undisclosed
Deal Type: Public Offering October 03, 2023
Details:
The net proceeds will fund the ongoing registrational trial for AN2025 (buparlisib), an oral pan-PI3K inhibitor that targets all class I PI3K isoforms, the milestone payments in connection with development of AN2025 and the commercial launch, if approved, of AN2025.
Lead Product(s): Buparlisib,Paclitaxel
Therapeutic Area: Oncology Product Name: AN2025
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Cantor Fitzgerald & Co.
Deal Size: $106.1 million Upfront Cash: Undisclosed
Deal Type: Public Offering September 29, 2023
Details:
The collaboration aims to focus on identifying subjects that could derive benefit from AN2025 (buparlisib) treatment in metastatic Squamous Cell Carcinoma of Head and Neck (SCCHN) patients and will expand to other indications and clinical trials.
Lead Product(s): Buparlisib,Paclitaxel
Therapeutic Area: Oncology Product Name: AN2025
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Nucleai
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership May 31, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
